Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
CLDX Hot Sheet
Rating Summary:5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 13 | New: 29
Merriman Curhan Ford issues comments on Celldex Therapeutics, Inc. (Nasdaq: CLDX) after Q3 results. The firm expect positive incremental catalysts in the near term. "Updated Phase II breast cancer data with CDX-011 (formerly Curagen's CRO-011) will be presented at the San Antonio Breast Cancer Symposium, December 9-13." The firm reiterated their Buy rating and $14-$15 price target.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
